Company intelligence / Profile preview
Qinghui Liannuo
Beijing, Beijing, Chinaunicetbio.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
QH104A (allogeneic universal CAR-γδ T cell therapy targeting CD276/B7H3) showed a 42.9% objective response rate and a 100% disease control rate in early (first-in-human) trial data for recurrent glioblastoma; orphan drug designation granted by the U.S. FDA in 2025; trial recruitment was suspended but initial data showed good durability and correlation with B7H3 expression.
- Therapeutic areas
- Oncology
- Modalities
- Universal CAR-TCell therapyAllogeneic T cell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Qinghui Liannuo.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qinghui Liannuo.